<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35597428</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-3913</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cellular signalling</Title>
          <ISOAbbreviation>Cell Signal</ISOAbbreviation>
        </Journal>
        <ArticleTitle>BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells.</ArticleTitle>
        <Pagination>
          <StartPage>110358</StartPage>
          <MedlinePgn>110358</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cellsig.2022.110358</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0898-6568(22)00120-6</ELocationID>
        <Abstract>
          <AbstractText>BTK inhibitors (BTKi) have dramatically improved outcomes for patients with chronic lymphocytic leukaemia (CLL) and some forms of B-cell lymphoma. However, new strategies are needed to enhance responses. Here we have performed a detailed analysis of the effects of BTKi on B-cell receptor (BCR)-induced signalling using primary malignant cells from CLL patients and B-lymphoma cell lines. Although BTK is considered as a key activator of PLCγ2, BTKi (ibrutinib and acalabrutinib) failed to fully inhibit calcium responses in CLL samples with strong BCR signalling capacity. This BTKi-resistant calcium signalling was sufficient to engage downstream calcium-dependent transcription and suppress CLL cell apoptosis and was entirely independent of BTK and not just its kinase activity as similar results were obtained using a BTK-degrading PROTAC. BTK-independent calcium signalling was also observed in two B-lymphoma cell lines where BTKi had little effect on the initial phase of the calcium response but did accelerate the subsequent decline in intracellular calcium. In contrast to BTKi, calcium responses were completely blocked by inhibition of SYK in CLL and lymphoma cells. Engagement of BTK-independent calcium responses was associated with BTK-independent phosphorylation of PLCγ2 on Y<sup>753</sup> and Y<sup>759</sup> in both CLL and lymphoma cells. Moreover, in CLL samples, inhibition of RAC, which can mediate BTK-independent activation of PLCγ2, cooperated with ibrutinib to suppress calcium responses. BTK-independent calcium signalling may limit the effectiveness of BTKi to suppress BCR signalling responses and our results suggest inhibition of SYK or dual inhibition of BTK and RAC as alternative strategies to strengthen pathway blockade.</AbstractText>
          <CopyrightInformation>Copyright © 2021. Published by Elsevier Inc.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Arthur</LastName>
            <ForeName>Rachael</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wathen</LastName>
            <ForeName>Alexander</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lemm</LastName>
            <ForeName>Elizabeth A</ForeName>
            <Initials>EA</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Stevenson</LastName>
            <ForeName>Freda K</ForeName>
            <Initials>FK</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Forconi</LastName>
            <ForeName>Francesco</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Linley</LastName>
            <ForeName>Adam J</ForeName>
            <Initials>AJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Physiology and Cell Signalling, University of Liverpool, Institute of Systems, Molecular and Integrative Biology, 5(th) Floor Nuffield Building, Crown Street, Liverpool L69 3BX, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Steele</LastName>
            <ForeName>Andrew J</ForeName>
            <Initials>AJ</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Packham</LastName>
            <ForeName>Graham</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom. Electronic address: gpackham@soton.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Valle-Argos</LastName>
            <ForeName>Beatriz</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Cell Signal</MedlineTA>
        <NlmUniqueID>8904683</NlmUniqueID>
        <ISSNLinking>0898-6568</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">B-cell receptor</Keyword>
        <Keyword MajorTopicYN="N">BTK</Keyword>
        <Keyword MajorTopicYN="N">Calcium</Keyword>
        <Keyword MajorTopicYN="N">Chronic lymphocytic leukaemia</Keyword>
        <Keyword MajorTopicYN="N">Lymphoma</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors report no relevant conflicts-of-interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>21</Day>
          <Hour>19</Hour>
          <Minute>26</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35597428</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cellsig.2022.110358</ArticleId>
        <ArticleId IdType="pii">S0898-6568(22)00120-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
